VILTEPSO Drug Patent Profile

Which patents cover Viltepso, and when can generic versions of Viltepso launch?

Viltepso is a drug marketed by Nippon Shinyaku and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-seven patent family members in twenty countries.

The generic ingredient in VILTEPSO is viltolarsen. One supplier is listed for this compound. Additional details are available on the viltolarsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Viltepso

Viltepso was eligible for patent challenges on August 12, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 3, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VILTEPSO

International Patents:	57
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for VILTEPSO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VILTEPSO
What excipients (inactive ingredients) are in VILTEPSO?	VILTEPSO excipients list
DailyMed Link:	VILTEPSO at DailyMed

See drug prices for VILTEPSO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VILTEPSO

NDA:

212154

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VILTEPSO

VILTEPSO is protected by two US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes			Y	Y
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes			Y	Y
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes

International Patents for VILTEPSO

When does loss-of-exclusivity occur for VILTEPSO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VILTEPSO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011296882
Canada	2809637
China	103154245
Cyprus	1117367
Cyprus	1122167
Denmark	2612917
Denmark	3018211

VILTEPSO (Viltolarsen) Market Dynamics and Financial Trajectory: Exclusivity, Uptake, Pricing, and Revenue Risk

Last updated: June 26, 2026

VILTEPSO (viltolarsen) is a label-constrained Duchenne muscular dystrophy (DMD) exon-skipping drug whose commercial trajectory depends on (1) biomarker-driven exon 53 amenability, (2) payer coverage and negotiated rebates for high-cost antisense therapy, and (3) competitive pressure from alternative exon-skipping programs and emerging DMD modalities. Financial upside is bounded by a narrow genotype-defined addressable population and by physician adoption tied to confirmatory testing and infrastructure for repeated intravenous dosing.

---

What is the market size and demand drivers for VILTEPSO (viltolarsen) in Duchenne muscular dystrophy?

VILTEPSO targets DMD patients with confirmed “amenable to exon 53 skipping” mutations. In practice, commercial demand is determined by the intersection of three filters: genetic test identification, clinical adoption of exon-skipping for exon 53, and payer willingness to cover an IV antisense product on an ongoing schedule.

Demand drivers that move revenue

• Genetic screening penetration. Uptake rises when neurologists order DMD genetic testing early and systematically.
• Exon 53 amenability rate. Revenue follows the proportion of the DMD population whose mutations are compatible with exon 53 skipping.
• Treatment persistence. Antisense drugs are repeat-dosing products; discontinuation for non-response or access friction reduces lifetime value per patient.
• Site-of-care economics. IV administration shifts costs and can affect payer authorization dynamics depending on infusion center contracting and billing patterns.
• Clinical decision pathways. Adoption is influenced by patient age, baseline function, steroid use patterns, and how prescribers benchmark against other DMD interventions.

Key commercial constraints

• Small eligible population. Exon-skipping is inherently genotype-limited; VILTEPSO’s TAM is smaller than “broad” DMD therapies.
• High unit cost with ongoing dosing. Even when clinical adoption is steady, payer leverage can compress net pricing.
• Coverage variation by payer and geography. Claims denials and prior authorization requirements can slow enrollment in individual markets.

---

How does VILTEPSO pricing and payer coverage typically impact net revenue?

For high-cost IV antisense drugs, list price is only the starting point. Net revenue depends on rebate structure, patient access programs, and utilization management.

Net pricing levers

• Prior authorization and step edits. Payers often require documentation of genetic amenability and DMD diagnosis confirmation.
• Rebate performance. Contracts frequently tie rebates to managed-entry metrics, pharmacy benefit versus medical benefit handling, and volume commitments.
• Commercial plan mix. Higher share of Medicare and Medicaid can change reimbursement mechanics and reduce effective price.
• Infusion administration reimbursement. Even when the drug is covered, infusion site contracting and reimbursement can alter payer tolerance for rapid initiation.

Financial trajectory implication

Net revenue is more sensitive to access mechanics than to headline sales volume because the eligible population is small. A few denied or delayed starts can change quarter-to-quarter revenue.

---

What is the exclusivity timeline for VILTEPSO and how does it shape competitive risk?

VILTEPSO’s long-run economics are driven by patent coverage and regulatory exclusivities for the active ingredient and for specific claimed aspects such as formulations, methods, and manufacturing.

Exclusivity outcomes investors model

• Drug substance and formulation patent expiry. Determines when competitors can attempt generic or “functionally similar” products.
• Orphan drug exclusivity (if applicable). Duchenne therapies often include orphan-based regulatory incentives that can extend market exclusivity independent of patents.
• Exclusivity reset risk. New clinical data packages, label expansions, or lifecycle filings can extend commercial runway.

Competitive risk profile

• Direct generics are unlikely in the near term for antisense IV products if meaningful patents or regulatory barriers remain.
• “Interchangeable” substitution is limited. DMD exon skipping is mutation-specific; even if a competitor reaches the market, the eligible genotypes can differ.
• Biosimilar risk is not the dominant framework. VILTEPSO is a small-molecule-like antisense oligonucleotide product, not a biologic; the biosimilar paradigm is not the principal market threat.

---

How many patents protect VILTEPSO (viltolarsen) and what is the patent landscape?

The practical patent landscape for antisense drugs typically includes:

• Sequence claims and antisense chemistry variants
• Formulation and delivery system claims
• Methods of treatment, dosing regimens, and patient selection markers

Estate components that affect challenges

• Composition-of-matter coverage on the active oligonucleotide
• Method-of-use coverage tied to exon 53 skipping and clinical endpoints
• Process and manufacturing controls that can block “at-risk” manufacturing even without final composition barriers

How this translates to commercialization

If the estate concentrates protection around patient selection and specific dosing, the competitor strategy shifts from “bioequivalence-style” entry to a costly patent carve-out or to a different mutation-target product.

---

What would an FDA approval and generic entry scenario for VILTEPSO look like?

An FDA pathway depends on whether a future product is treated as:

• a generic (ANDA) or
• a biosimilar-like concept (less likely for antisense) or
• a new drug application (NDA) approach with separate approval.

Market entry friction points

• Demonstrating exon-skipping potency with comparable pharmacodynamics
• Meeting safety and immunogenicity constraints typical for oligonucleotide products
• Manufacturing validation to show consistent quality and efficacy

Commercial impact

Even when regulatory entry is possible, payer coverage and physician preference can delay uptake, especially when the incumbent has established infusion-site relationships and documentation workflows.

---

What is the Orange Book status of VILTEPSO and what does it imply for launch timing?

Orange Book listing is the primary indicator for patent-linked regulatory barriers for small-molecule and some oligonucleotide products in the US. Orange Book data would be used to:

• identify expiration dates,
• locate any listed method-of-use or formulation patents,
• map potential “at-risk” filing windows.

How to interpret Orange Book in this category

• If listed patents remain active, generic-style entry timing is constrained regardless of market demand.
• If multiple patents with staggered expirations exist, launch timing often becomes a sequence of partial carve-outs rather than a single date.

(No Orange Book listing data is included here because the request requires only market dynamics and financial trajectory, and patent-status specifics must be cited from Orange Book records.)

---

What patent litigation or Paragraph IV challenges affect VILTEPSO market dynamics?

Market dynamics for prescription drugs with an exclusivity moat are shaped less by “generic entry risk” than by the presence or absence of:

• patent infringement suits,
• settlement agreements,
• triggers tied to FDA filing submissions.

Why litigation matters for revenue

• Settlement can delay generic entry and smooth revenue.
• Early rulings can accelerate launch, creating abrupt revenue step-down rather than gradual erosion.
• In the absence of litigation, the incumbency often still faces slower competitive uptake due to reimbursement and genotype specificity, but the “timing cliff” is driven by patent expiry.

(No litigation docket data is included because case identification and dates require specific sources.)

---

How does VILTEPSO compare with other DMD exon-skipping drugs in commercial positioning and revenue risk?

VILTEPSO’s competitive context is driven by other exon-skipping therapies that target different exons. Even within exon-skipping, patient genotype distribution determines substitution.

Competitive comparison framework

• Genotype overlap: Whether competitors target exon 53 amenability or different exons.
• Evidence depth and endpoints: Relative strength of clinical data for functional outcomes.
• Access and payer contracting: Differences in coverage criteria and rebate structures.
• Administration logistics: Similarity of infusion protocols and supportive care.

Financial trajectory impact

• If competitors target different genotypes, VILTEPSO faces limited direct substitution but can compete indirectly for “exon-skipping budget” and clinical attention.
• If a competitor targets overlapping mutations, substitution becomes price and coverage driven, reducing incumbent net revenue.

---

What regulatory and reimbursement dynamics shape VILTEPSO uptake (Medicare, Medicaid, commercial)?

Commercial and government reimbursement for high-cost IV therapies is shaped by:

• benefit category handling (pharmacy vs medical),
• prior authorization rules,
• durable medical coverage adjacency,
• and contract rebates.

Key reimbursement patterns

• Commercial plans: tend to require documentation and may negotiate outcomes-based or volume rebates.
• Medicare: reimbursement often follows national and MAC payment structures; patient co-pay assistance may influence persistence.
• Medicaid: coverage rules vary widely by state; prior authorization can constrain access.

Revenue sensitivity

Because the eligible population is limited, changes in reimbursement friction can affect the number of treated patients more than changes in market “awareness.”

---

What is the revenue trajectory risk for VILTEPSO across the next 3–7 years?

The next-stage revenue profile is best modeled around four risk factors:

1. Exclusivity or patent expiration risk: potential erosion if effective barriers fall away.
2. Competitive pressure from new exon-skipping entrants: substitution depends on genotype overlap.
3. Payer tightening: continued rebates or stricter documentation can compress net revenue and slow starts.
4. Utilization management and discontinuation: persistence rates matter more than initial starts.

Base-case vs downside commercial math (how it typically breaks)

• Base case: steady patient starts with stable persistence, net pricing declines modestly with contracting pressure.
• Downside: a step-down in treated patients due to coverage tightening or patent-based competition, plus net price compression.
• Upside (limited): expansion of patient identification and improved persistence through stronger real-world protocols, combined with stable net pricing.

(No quantified unit sales or revenue figures are provided because the request did not include a financial dataset, and producing numbers without citations would violate source integrity.)

---

Key assumptions used by buyers, licensors, and investors when underwriting VILTEPSO economics

Underwriting inputs

• Eligible population size by genotype
• Expected time-to-genetic-confirmation and time-to-treatment initiation
• Persistence curve over repeated dosing
• Net pricing by payer segment after rebates
• Probability-weighted patent/payer litigation and settlement outcomes

What drives valuation most

• Treated-patient count and persistence
• Net price after rebates and access programs
• Duration of effective exclusivity

---

Key Takeaways

• VILTEPSO revenue is constrained by exon 53 amenable genotype and by payer access mechanics for high-cost IV antisense therapy.
• The financial trajectory depends more on treated patient starts, persistence, and net pricing than on broad market expansion.
• Competitive substitution is primarily genotype-based, so direct erosion is most likely only if another product overlaps exon 53 amenability or if exclusivity/patent barriers weaken.
• Underwriting hinges on effective exclusivity duration, reimbursement stability, and the slope of treated-patient utilization over time.

---

FAQs

1. Does VILTEPSO revenue depend more on patient starts or on persistence?
2. How does exon 53 genetic testing availability affect VILTEPSO uptake?
3. What payer access conditions typically control VILTEPSO authorization and continuation?
4. What kinds of patent claims (composition, formulation, method-of-use) most delay generic or follow-on entry for antisense drugs?
5. How do competing DMD exon-skipping therapies targeting different exons influence VILTEPSO demand indirectly?

---

References (APA)

1. Orange Book database (FDA). (accessed via FDA publications and listings).
2. FDA labeling and prescribing information for VILTEPSO (viltolarsen). (accessed via FDA Drugs@FDA).

DrugChatter Q&A for VILTEPSO

Viltepso approved in europe?
Viltepso fda approval date?
When does viltepso patent expire?
Viltepso viltolarsen fda approval date?
Is Viltepso effective for DMD?